126 related articles for article (PubMed ID: 26073421)
1. High Frequency of Severe Telaprevir-associated Skin Eruptions in Clinical Practice.
Carrascosa R; Capusan TM; Llamas-Velasco M; García-Buey L; Gordillo C; Sánchez-Pérez J
Acta Derm Venereol; 2016 Jan; 96(1):97-9. PubMed ID: 26073421
[TBL] [Abstract][Full Text] [Related]
2. [Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
Lorcy S; Gaudy-Marqueste C; Botta D; Portal I; Quiles N; Oulies V; Mancini J; Grob JJ; Richard MA
Ann Dermatol Venereol; 2016 May; 143(5):336-46. PubMed ID: 27161648
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir-related dermatitis.
Roujeau JC; Mockenhaupt M; Tahan SR; Henshaw J; Martin EC; Harding M; van Baelen B; Bengtsson L; Singhal P; Kauffman RS; Stern RS
JAMA Dermatol; 2013 Feb; 149(2):152-8. PubMed ID: 23560295
[TBL] [Abstract][Full Text] [Related]
4. Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study.
Toro Montecinos M; Carrascosa Carrillo JM; Vilavella Rius M; Bielsa Marsol I; Plana Pla A; Morillas Cunill R; Planas Vilà R; Masnou Ridaura H; López Escartin D; Ferrándiz Foraster C
Actas Dermosifiliogr; 2015 Apr; 106(3):219-25. PubMed ID: 25444579
[TBL] [Abstract][Full Text] [Related]
5. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.
Torii H; Sueki H; Kumada H; Sakurai Y; Aoki K; Yamada I; Ohtsuki M
J Dermatol; 2013 Aug; 40(8):587-95. PubMed ID: 23734933
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment.
Biesbroeck LK; Scott JD; Taraska C; Moore E; Falsey RR; Shinohara MM
Am J Clin Dermatol; 2013 Dec; 14(6):497-502. PubMed ID: 23775427
[TBL] [Abstract][Full Text] [Related]
7. Severe cutaneous eruptions on telaprevir.
Chen ST; Wu PA
J Hepatol; 2012 Aug; 57(2):470-2. PubMed ID: 22387663
[No Abstract] [Full Text] [Related]
8. Dermatological side-effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir.
Bernardeschi C; Valeyrie-Allanore L; Ortonne N; Gressier L; Wallet-Faber N; Bernard PH; Hezode C; Duclos-Vallée JC; Samuel D; Mallet V; Pol S; Milpied B; Dupin N
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):143-6. PubMed ID: 25187266
[No Abstract] [Full Text] [Related]
9. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Macías J; Rivero A
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
[TBL] [Abstract][Full Text] [Related]
10. Widespread morbilliform eruption associated with telaprevir: use of dermatologic consultation to increase tolerability.
Strazzula L; Pratt DS; Zardas J; Chung RT; Thiim M; Kroshinsky D
JAMA Dermatol; 2014 Jul; 150(7):756-9. PubMed ID: 24718650
[TBL] [Abstract][Full Text] [Related]
11. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Hashimoto Y; Kanto H; Itoh M
J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
[TBL] [Abstract][Full Text] [Related]
12. Drug rash with eosinophilia and systemic symptoms due to telaprevir.
Montaudié H; Passeron T; Cardot-Leccia N; Sebbag N; Lacour JP
Dermatology; 2010; 221(4):303-5. PubMed ID: 20798484
[TBL] [Abstract][Full Text] [Related]
13. Eruptive seborrheic keratoses secondary to telaprevir-related dermatitis.
Chadwick PW; Heymann WR
Cutis; 2016 Aug; 98(2):E20-1. PubMed ID: 27622264
[No Abstract] [Full Text] [Related]
14. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
Tavakoli-Tabasi S; Bagree A
J Clin Gastroenterol; 2012 Feb; 46(2):162-7. PubMed ID: 21814144
[TBL] [Abstract][Full Text] [Related]
15. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
[TBL] [Abstract][Full Text] [Related]
16. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
Cachay ER; Wyles DL; Torriani FJ; Ballard C; Colwell B; Lin JC; Hill L; Mathews WC
AIDS; 2013 Nov; 27(18):2893-7. PubMed ID: 23842130
[TBL] [Abstract][Full Text] [Related]
17. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS
J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus.
Takita M; Hagiwara S; Kudo M; Kouno M; Chishina H; Arizumi T; Kitai S; Yada N; Inoue T; Minami Y; Ueshima K
Oncology; 2014; 87 Suppl 1():110-7. PubMed ID: 25427742
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
Dutilh JC; Arends JE
Neth J Med; 2013 Sep; 71(7):391-2. PubMed ID: 24038569
[No Abstract] [Full Text] [Related]
20. Management of refractory telaprevir-induced dermatitis using oral corticosteroids.
Garcias-Ladaria J; Pérez-Ferriols A; Ortega-García P; Diago M
Actas Dermosifiliogr; 2014 Nov; 105(9):e55-60. PubMed ID: 24786187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
